Endogenous Nampt upregulation is associated with diabetic nephropathy inflammatory‑fibrosis through the NF‑κB p65 and Sirt1 pathway; NMN alleviates diabetic nephropathy inflammatory‑fibrosis by inhibiting endogenous Nampt
Authors:
Open Access
- 1 September 2017
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (5) , 4181-4193
Abstract
Nicotinamide phosphoribosyltransferase (Nampt) is a key enzyme in the nicotinamide adenine dinucleotide (NAD+) biosynthetic pathway. Exogenous extra cellular Nampt has been reported to increase the synthesis of pro‑fibrotic molecules in various types of renal cells. However, the role of endogenous Namptenzymatic activity in diabetic renal cells, particularly those associated with inflammation and fibrosis through the nuclear factor (NF)‑κB p65 and sirtuin 1 (Sirt1) pathway is still unknown. In the present study, a possible mechanism by which endogenous Nampt upregulation affects the expression of pro‑inflammatory and pro‑fibrotic cytokines in vivo and in vitro, is reported. The present results demonstrate that the expression of vimentin and fibronectin was directly implicated in endogenous Nampt upregulation. The expression levels of Poly(ADP‑ribose) polymerase‑1, NF‑κB p65, forkhead box protein O1 and B‑cell lymphoma 2‑like protein 4 were also significantly increased at 96 h compared with control group (P<0.01) respectively in response to endogenous Nampt upregulation. Furthermore, the expression level of Sirt1 was significantly reduced (P<0.05), and the NAD and NADH levels, and the NAD/NADH ratio are significantly altered in STZ‑induced diabetic rats (P<0.01). Treatment with FK866 and nicotinamide mononucleotide (NMN) led to downregulation of vimentin and fibronectin, respectively. These results suggest a novel role of Nampt as a pro‑inflammatory cytokine of mesangial fibrotic signaling. The Nampt‑NF‑κB p65 and Sirt1 signaling pathway serves a pivotal role in affecting the expression of fibrosis factors in diabetic nephropathy (DN) glomerular fibrosis processing. It is also suggested that prevention of endogenous Nampt upregulation may be critical in the treatment of DN pro‑inflammatory fibrosis and NMN is likely to be a potential pharmacological agent for the treatment of resistant DN nephritic fibrosis.Keywords
This publication has 34 references indexed in Scilit:
- Regulation of FOXOs and p53 by SIRT1 Modulators under Oxidative StressPLOS ONE, 2013
- Expression and Regulation of Nampt in Human IsletsPLOS ONE, 2013
- The Adipocytokine Nampt and Its Product NMN Have No Effect on Beta-Cell Survival but Potentiate Glucose Stimulated Insulin SecretionPLOS ONE, 2013
- Integrin α1/Akita double-knockout mice on a Balb/c background develop advanced features of human diabetic nephropathyKidney International, 2012
- Sirtuin 1 Modulates Cellular Responses to Hypoxia by Deacetylating Hypoxia-Inducible Factor 1αMolecular Cell, 2010
- SIRT1 is a redox‐sensitive deacetylase that is post‐translationally modified by oxidants and carbonyl stressThe FASEB Journal, 2010
- Circadian Control of the NAD + Salvage Pathway by CLOCK-SIRT1Science, 2009
- Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-agingAgeing Research Reviews, 2008
- Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic EnzymeCell Metabolism, 2007
- Insulin gene mutations as a cause of permanent neonatal diabetesProceedings of the National Academy of Sciences, 2007